Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay.
Yunwei LiNagashree KsGowramma ByranPraveen Thaggikuppe KrishnamurthyPublished in: Applied biochemistry and biotechnology (2022)
The clinically used glitazones (rosiglitazone and pioglitazone) for type 2 diabetes mellitus therapy have been linked to serious side effects such as fluid retention, congestive heart failure, weight gain, bone loss, and an increased risk of bladder cancer. The complete activation of PPAR-γ receptors in target tissues is linked to these effects. Many studies have demonstrated that partial PPAR-γ activators (GW0072, PAT5A, GQ16) give equivalent therapeutic benefits to full PPAR-γ agonists without the associated side effects. These breakthroughs cleared the path for the development of partial agonists or selective PPAR-γ modulators (SPPARγMs). This study combined pharmacophore modeling, molecular docking, and an adipogenesis experiment to identify thiazolidine analogs as SPPARMs/partial agonists. A custom library of 220 molecules was created and virtual screened to discover 90 compounds as SPPARγMs/ partial agonists. The chosen eight compounds were synthesized and tested for adipogenesis using 3T3L1 cell lines. These compounds' partial agonistic activity was evaluated in 3T3L1 cell lines by comparing their capacity to stimulate PPAR-γ mediated adipogenesis to that of a full agonist, rosiglitazone. The findings of the adipogenesis experiment demonstrate that all eight compounds examined had a partial potential to stimulate adipogenesis when compared to the full agonist, rosiglitazone. The current investigation identified eight possible PPAR-γ partial agonists or SPPARγMs that may be effective in the treatment of type 2 diabetes mellitus.
Keyphrases
- molecular docking
- insulin resistance
- molecular dynamics simulations
- high fat diet induced
- heart failure
- weight gain
- multiple sclerosis
- mass spectrometry
- fatty acid
- ms ms
- small molecule
- body mass index
- bone loss
- adipose tissue
- gene expression
- mesenchymal stem cells
- type diabetes
- metabolic syndrome
- cardiovascular disease
- high throughput
- stem cells
- molecular dynamics
- single cell
- skeletal muscle
- glycemic control
- smoking cessation